Decision on rights issue subject to approval at Extraordinary General Meeting
On September 22, 2016, the Board of Oncology Venture Sweden AB ("Oncology Venture") decided to – subject to approval at Extraordinary General Meeting – conduct a rights issue of up to 774 984 shares at an issue price of 29.00 SEK per share. Fully subscribed rights issue provides Oncology Venture approximately 22,5 million SEK before issuing costs. Beforehand, the company has agreed on subscription commitments amounting to approximately 12,1 million SEK, which equals about 54 % of the rights issue’s total volume. Notice of Extraordinary General Meeting will be published shortly. In view of the